REHOVOT, Israel, Sept. 13, 2016 -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it has entered into an agreement with the University of Missouri to collect and sequence soil samples from several university field sites. The soil samples represent previously untapped sources for microbial diversity from one of the primary corn growing regions of the United States. Under the agreement, Evogene will utilize the results as an additional novel source of leads for its microbial data base supporting its Insect Control and Ag-biological product programs.
Activities associated with the collecting and sampling of the soil will be led by Evogene's R&D site in St. Louis and will be performed in several different field sites situated across the state of Missouri. The unique set of research stations includes field sites with diverse range of insects, crops, and environments.
"We are excited to collaborate with Evogene, a leading Israeli biotechnology company focusing on crop improvement," said Dr. Marc Linit, Senior Associate Dean for Research and Extension. "Collaboration with Evogene to discover novel soil-borne microbes will lead to the development of new bio-based insect control and other ag-based biological programs that will benefit farmers in Missouri and elsewhere."
"As we continue to expand our activities in the US, we are very pleased to be joining forces with the University of Missouri in a unique project bringing together world class academic researchers in agricultural science with one of the industry's most advanced computational discovery groups," said Ofer Haviv, Evogene President and CEO. "Tapping into the diversity of University of Missouri's field sites introduces a new source of microbial leads for our already extensive database, allowing us to strengthen the potential novelty of our product offering in the area of insect control and ag-biologicals."
About Evogene Ltd.:
Evogene (NYSE:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at [email protected].
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Eyal Leibovitz, CFO E: [email protected] T: +972 8931 1900


MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
First Western Ship Transits Strait of Hormuz Since Iran War Began
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Apple Turns 50: From Garage Startup to AI Crossroads
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 



